ALXO on Nasdaq
ALX ONCOLOGY HOLDINGS INC
$0.95 up 0.06 (6.48%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 16, 2026.
Overview
Compare with Bioline Rx Ltd., Neuphoria Therapeutics Inc. or Longeveron Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2022
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | $77.0M | $116.4M | $141.8M |
| General and administrative | $23.9M | $26.1M | $28.5M |
| Impairment charge | $3.2M | ||
| Total operating expenses | $104.0M | $142.5M | $170.3M |
| Loss from operations | -$104.0M | -$142.5M | -$170.3M |
| Interest income | $4.0M | $9.4M | $10.6M |
| Interest expense | -$1.6M | -$1.7M | -$1.6M |
| Other income (expense), net | -$36.0K | -$20.0K | $389.0K |
| Loss before income taxes | -$101.7M | -$134.8M | -$160.8M |
| Income tax provision | $0 | $0 | $0 |
| Net loss | -$101.7M | -$134.8M | -$160.8M |
| Net loss per share, basic | -$1.90 | -$2.58 | -$3.74 |
| Net loss per share, diluted | -$1.90 | -$2.58 | -$3.74 |
| Weighted-average shares of common stock used to compute net loss per share, basic | 53.7M shares | 52.2M shares | 43.0M shares |
| Weighted-average shares of common stock used to compute net loss per share, diluted | 53.7M shares | 52.2M shares | 43.0M shares |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $16.4M | $17.6M | $22.4M |
| Short-term investments | $28.4M | $110.2M | |
| Prepaid expenses and other current assets | $5.9M | $6.6M | |
| Total current assets | $50.7M | $134.4M | |
| Property and equipment, net | $1.2M | $2.9M | |
| Long-term investments | $3.5M | $3.5M | |
| Other assets | $3.6M | $7.0M | |
| Total assets | $59.0M | $147.8M | |
| Accounts payable | $4.9M | $4.5M | |
| Payable and accrued liabilities due to related party | $0 | $149.0K | |
| Term loan, current | $5.2M | $435.0K | |
| Accrued expenses and other current liabilities | $14.4M | $13.4M | |
| Total current liabilities | $24.6M | $18.5M | |
| Term loan, non-current, net | $4.5M | $9.5M | |
| Other non-current liabilities | $4.0M | $6.2M | |
| Total liabilities | $33.1M | $34.2M | |
| Common stock, $0.001 par value; 1,000,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 54,388,022 and 53,052,912 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $54.0K | $53.0K | |
| Additional paid-in capital | $748.7M | $734.4M | |
| Accumulated other comprehensive income | $28.0K | $275.0K | |
| Accumulated deficit | -$722.8M | -$621.1M | |
| Total stockholders equity | $26.0M | $113.6M | $189.7M |
| Total liabilities and stockholders equity | $59.0M | $147.8M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.0B shares | 1.0B shares | |
| Common stock, shares issued | 54.4M shares | 53.1M shares | |
| Common stock, shares outstanding | 54.4M shares | 53.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$101.7M | -$134.8M | -$160.8M |
| Stock-based compensation | $12.6M | $27.1M | $26.3M |
| Depreciation and amortization | $706.0K | $872.0K | $836.0K |
| Non-cash lease costs | $1.7M | $1.8M | $1.3M |
| Net accretion of discounts on investments | -$1.2M | -$4.7M | -$6.5M |
| Accretion of term loan discount and issuance costs | $280.0K | $265.0K | $250.0K |
| Impairment charge | $3.2M | ||
| Loss on disposal of fixed asset | $10.0K | ||
| Prepaid expenses and other current assets | $658.0K | -$692.0K | -$1.3M |
| Other assets | -$686.0K | $7.4M | $1.4M |
| Accounts payable | $421.0K | -$4.0M | $458.0K |
| Payable and accrued liabilities due to related party | -$149.0K | -$394.0K | -$1.1M |
| Accrued expenses and other current liabilities | $2.0M | -$12.6M | $11.2M |
| Other non-current liabilities | -$1.9M | -$2.1M | -$2.4M |
| Net cash used in operating activities | -$84.1M | -$121.9M | -$130.4M |
| Purchase of investments | -$51.6M | -$107.4M | -$246.6M |
| Maturities of investments | $134.4M | $194.1M | $292.6M |
| Purchase of property and equipment | -$212.0K | -$447.0K | -$1.3M |
| Net cash provided by investing activities | $82.6M | $86.3M | $44.7M |
| Proceeds from equity offerings, net of underwriter discounts ($3,795 thousand) and issuance costs ($567 thousand) | $58.9M | ||
| Proceeds from ATM offering, net of commissions | $1.7M | $29.7M | |
| Proceeds from exercise of stock options under equity incentive plan | $14.0K | $1.6M | $269.0K |
| Proceeds from issuance of common stock under employee stock purchase plan | $24.0K | $351.0K | $523.0K |
| Principal payments on finance leases | -$929.0K | -$827.0K | -$388.0K |
| Principal payments on term loan | -$435.0K | ||
| Net cash provided by financing activities | $362.0K | $30.8M | $59.3M |
| Net (decrease) in cash, cash equivalents and restricted cash | -$1.2M | -$4.8M | -$26.4M |
| Cash paid for interest | $1.3M | $1.4M | $1.2M |
| Purchase of property and equipment in accounts payable and accrued expenses | $962.0K | $1.2M | $1.4M |
| Right-of-use asset (modified) acquired under finance leases | -$182.0K | $1.3M | $2.6M |
| Underwriter discounts | $3.8M | ||
| Issuance costs | $567.0K |
Recent filings
- Aug 18, 20264
- Aug 18, 20264
- Aug 14, 2026SCHEDULE 13G/A
- Aug 6, 20268-K
- Aug 6, 202610-Q
- Jul 27, 2026SCHEDULE 13G
- Jul 6, 20264
- Jun 30, 20268-K
- Jun 26, 20268-K
- Jun 11, 20268-K
- May 27, 2026SCHEDULE 13D/A
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 8, 20268-K
- May 8, 202610-Q
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceALXO quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11